Systemic Treatment - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Systemic Treatment

The Experts below are selected from a list of 271059 Experts worldwide ranked by ideXlab platform

Systemic Treatment – Free Register to Access Experts & Abstracts

John H. Edmonson – One of the best experts on this subject based on the ideXlab platform.

  • Progress in the Systemic Treatment of advanced soft-tissue sarcomas
    Cancer Control, 1998
    Co-Authors: Scott H. Okuno, John H. Edmonson
    Abstract:

    Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current Systemic Treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better Systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the Systemic Treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality Treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.

Gabe S. Sonke – One of the best experts on this subject based on the ideXlab platform.

  • Doctors’ reports about palliative Systemic Treatment: A medical record study.
    Palliative medicine, 2016
    Co-Authors: Hilde M. Buiting, Mirian Brink, Marleen N Wijnhoven, Martine E Lokker, Lydia Gm Van Der Geest, Wim E Terpstra, Gabe S. Sonke
    Abstract:

    Background:Decisions about palliative Systemic Treatment are key elements of palliative and end-of-life care. Such decisions must often be made in complex, clinical situations.Aim:To explore the content of medical records of patients with advanced non-small cell lung cancer and pancreatic cancer with specific emphasis on doctors’ notes about decisions on palliative Systemic Treatment.Design:Medical record review (2009–2012) of 147 cancer patients containing 276 notes about palliative Systemic Treatment. We described the proportion of notes/medical records containing pre-specified items relevant to palliative Systemic Treatment. We selected patients using the nationwide Netherlands Cancer Registry.Setting:Hospital based.Results:About 75% of all notes reported doctors’ considerations to start/continue palliative Systemic Treatment, including information about the prognosis (47%), possible survival gain (22%), patients’ wish for palliative Systemic Treatment (33%), impact on quality of life (8%), and patient…

  • marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant Systemic Treatment in breast cancer patients the mari procedure
    Annals of Surgery, 2015
    Co-Authors: M Donker, Gabe S. Sonke, Marieke E Straver, Jelle Wesseling, Claudette E Loo, Margaret Schot, C A Drukker, Harm Van Tinteren, Emiel Th J Rutgers, Mariejeanne Vrancken T F D Peeters
    Abstract:

    Objective:The MARI procedure [marking the axillary lymplymphe with radioactive iodiiodine (125I) seeds] is a new minimal invasive method to assess the pathological response of nodal metastases after neoadjuvant Systemic Treatment (NST) in patients with breast cancer. This method allows axilla-conserving

Scott H. Okuno – One of the best experts on this subject based on the ideXlab platform.

  • Progress in the Systemic Treatment of advanced soft-tissue sarcomas
    Cancer Control, 1998
    Co-Authors: Scott H. Okuno, John H. Edmonson
    Abstract:

    Background: Despite the plethora of chemotherapeutic remedies for advanced soft-tissue sarcomas, little evidence has developed to indicate that these efforts have been curative. No controlled comparison has yet proven that patients receiving multidrug regimens survive longer than those receiving doxorubicin alone. Methods: The authors review current Systemic Treatments and then discuss some investigational efforts now in progress. Also, they seek to demonstrate how the therapies currently available can be integrated with surgery and radiation therapy to accomplish more than might be anticipated from chemotherapy alone. Results: While working to develop better Systemic therapies for advanced soft-tissue sarcomas, the integrated use of our best chemotherapy regimens in combination with selected surgical and radiotherapy efforts may provide patients with the best available therapy. Some recent observations involving the use of molgramostim plus chemotherapy have been intriguing. Conclusions: Progress in the Systemic Treatment of advanced soft-tissue sarcomas may be gradual, but it is real. Our daily challenge is to be certain that we offer each patient the best available multimodality Treatment applicable to his or her clinical situation. Molgramostim should be made available for further study with chemotherapy in controlled clinical trials.

Winette T. A. Graaf – One of the best experts on this subject based on the ideXlab platform.

Á. León – One of the best experts on this subject based on the ideXlab platform.

  • Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study.
    Actas dermo-sifiliograficas, 2018
    Co-Authors: A. Batalla, Rosa Fernández-torres, L. Rodríguez-pazos, Benigno Monteagudo, R. Pardavila-riveiro, Romina Rodríguez-lojo, A. Zulaica, Miguel Cabanillas, Eduardo Fonseca, Á. León
    Abstract:

    Abstract Background and objective Studies on the use of Systemic therapy for psoriasis in pediatric patients are scarce. The main aim of this study was to describe the Systemic Treatments used for moderate to severe psoriasis in pediatric clinical settings. The second aim was to describe the effectiveness and safety of these Treatments. Material and methods Descriptive, cross-sectional, multicenter study of patients under 18 years of age with moderate to severe psoriasis who were being treated or had been treated with a Systemic drug (conventional or biologic) or phototherapy. We recorded demographic and clinical information, Treatments received, tolerance, adverse effects, and response to Treatment. Results Data were collected for 40 patients (60% female; mean age, 13 years) who had received 63 Treatments in total. The most common first Treatment (n = 40) was phototherapy (administered to 68% of patients), followed by acitretin (15%). The most common Treatments overall (n = 63) were phototherapy (57%) and methotrexate (16%). At week 12 (evaluation of Systemic Treatment and phototherapy), 66% of the patients were classified as good responders and 22% as partial responders. The respective rates for week 24 (evaluation of Systemic Treatment only) were 36% and 32%. The Treatments were well tolerated (97%) and adverse effects were reported in just 11% of cases. There were no Treatment discontinuations because of adverse effects. Conclusions Phototherapy, followed by methotrexate, were the most common Treatment for moderate to severe psoriasis in this series of patients under 18 years. The Treatments showed a favorable safety profile and were associated with a good response rate of 66% at week 12 (Systemic Treatment and phototherapy) and 36% at week 24 (Systemic Treatment only).